Multisociety (AATS, ACCF, SCAI, and STS) Expert Consensus Statement: Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part 1: Transcatheter Aortic Valve Replacement

*J. Am. Coll. Cardiol.* 2012;59;2028-2042; originally published online Mar 1, 2012; doi:10.1016/j.jacc.2012.02.016

**This information is current as of May 23, 2012**

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://content.onlinejacc.org/cgi/content/full/59/22/2028
COMPETENCE STATEMENT

Multisociety (AATS, ACCF, SCAI, and STS)
Expert Consensus Statement:
Operator and Institutional Requirements for
Transcatheter Valve Repair and Replacement,
Part 1: Transcatheter Aortic Valve Replacement

Carl L. Tommaso, MD1*
R. Morton Bolman, III, MD2
Ted Feldman, MD3
Joseph Bavaria, MD4
Michael A. Acker, MD4
Gabriel Aldea, MD5
Duke E. Cameron, MD6
Larry S. Dean, MD5
Dave Fullerton, MD7
Ziyad M. Hijazi, MD8
Eric Horlick, MD9
D. Craig Miller, MD10
Marc R. Moon, MD11
Richard Ringel, MD6
Carlos E. Ruiz, MD, PhD12
Alfredo Trento, MD13
Bonnie H. Weiner, MD14
Evan M. Zahn, MD15

Preamble

The granting of staff privileges to physicians is an important mechanism to ensure quality care. The Joint Commission on Accreditation of Healthcare Organizations requires that medical staff privileges be based on professional criteria specified in medical staff bylaws. Physicians are charged with defining the criteria that constitute professional competence and with evaluating their peers accordingly. With the evolution of transcatheter aortic valve replacement (TAVR), an important opportunity arises for both cardiologists and surgeons to come together to identify the criteria for performing these procedures. The Society for Cardiovascular Angiography and Interventions (SCAI), American Association for Thoracic Surgery (AATS), American College of Cardiology Foundation (ACCF), and The Society of Thoracic Surgeons (STS) have, therefore, joined together to provide recommendations for institutions to assess their potential for instituting and/or maintaining a transcatheter valve program. This article concerns TAVR. As TAVR is in its infancy, there are few data on which to base this consensus statement. Therefore, many of these recommendations are based on expert consensus. As the procedures evolve, technology changes, experience grows, and more data is accumulated, there will certainly be a need to update this consensus statement. However, with the Food and Drug Administration (FDA) having just approved the first generation of TAVR devices, the writing committee and participating societies believe that the recommendations listed in this report serve as an appropriate starting point. In some ways, these recommendations apply to institutions more than to individuals. As there is a strong consensus that these new valve therapies are best performed using a team approach, these credentialing criteria may be best applied.

From the 1Division of Cardiology, NorthShore University HealthSystem, Skokie Hospital, Skokie, Illinois; 2Division of Cardiac Surgery, Brigham and Women’s Hospital, Boston, Massachusetts; 3Division of Cardiology, NorthShore University HealthSystem, Evanston Hospital, Evanston, Illinois; 4Division of Cardiothoracic Surgery, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; 5Division of Cardiothoracic Surgery, University of Colorado, Aurora, Colorado; 6Division of Cardiovascular Surgery, Johns Hopkins Hospital, Baltimore, Maryland; 7Division of Cardiology, University of Maryland Hospital, Baltimore, Maryland; 8Division of Pediatric Cardiology, Rush University Medical Center, Chicago, Illinois; 9Division of Cardiology, St. Louis University School of Medicine, St. Louis, Missouri; 10Division of Cardiovascular Surgery, Cedars Sinai Medical Center, Los Angeles, California; 11Division of Pediatric Cardiology, Saint Vincent Hospital at Worcester Medical Center, Harvard, Massachusetts; 12Division of Pediatric Cardiology, Miami Children’s Hospital, Miami, Florida.

This article is copublished in Catheterization and Cardiovascular Interventions, The Journal of Thoracic and Cardiovascular Surgery, and The Annals of Thoracic Surgery.

Conflict of interest: See Appendices.

*Correspondence to: Carl L. Tommaso, MD, Cardiac Catheterization Laboratory, NorthShore University HealthSystem Skokie Hospital, 9669 N. Kenton Avenue, Skokie, IL 60076. E-mail: ctommaso@northshore.org.

Downloaded from content.onlinejacc.org by on May 23, 2012
at the institutional level. Partnering societies used the ACCF’s policy on relationships with industry and other entities (RWI) to author this document (http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx). To avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee, all members of the writing committee, as well as peer reviewers of the document, were asked to disclose all current healthcare-related relationships, including those existing 12 months before initiation of the writing effort. A committee of interventional cardiologists and surgeons was formed to include a majority of members with no relevant RWI and be led by an interventional cardiology co-chair and a surgical co-chair with no relevant RWI. Authors with relevant RWI were not permitted to draft or vote on text or recommendations pertaining to their RWI. RWI were reviewed on all conference calls and updated as changes occurred. Author and peer reviewer RWI pertinent to this document are disclosed in Appendices 1 and 2, respectively. In addition, to ensure complete transparency, authors’ comprehensive disclosure information (including RWI not pertinent to this document) is available as an online supplement to this document. The work of the writing committee was supported exclusively by the partnering societies without commercial support. Writing committee members volunteered their time to this effort. Conference calls of the writing committee were confidential and attended only by committee members. SCAI, AATS, ACCF, and STS believe that adherence to these recommendations will maximize the chances that these therapies will become a successful part of the armamentarium for treating valvular heart disease in the United States. In addition, these recommendations will hopefully facilitate optimum quality during the delivery of this therapy, which will be important to the development and successful implementation of future, less invasive approaches to structural heart disease.

Introduction

Enabled by the development of new technologies, treatment of valvular heart disease by transcatheter techniques is becoming a favored approach of cardiac providers, resulting in less invasive treatment for patients previously treatable only with open heart surgery or, in many cases, not treatable at all. Recognition from the medical community of the applicability, effectiveness, and practicality of catheter-based transcatheter valve therapies has further increased interest in these treatments. Training program content, standards, credentialing, and board certifications for cardiac surgical procedures and percutaneous coronary intervention (PCI) are well developed, but no such structure exists in the field of percutaneous structural or valvular heart disease therapies. The purpose of this article is to outline criteria for operator and institutional requirements to enable institutions and providers to participate responsibly in this new and rapidly developing field.

The emergence of transcatheter aortic valve repair and implantation as an alternative to traditional surgical therapy for valvular diseases has been facilitated by innovative devices, rapidly developing techniques, and careful patient selection (1). The combination of interventional skills, equipment, collaborative clinical management, surgical approaches, techniques, and decision-making distinguish the qualifications to participate in this field as unique, as does the complexity of the patients requiring these therapies (1–3). Given both the high-risk nature of these catheter interventions and the availability of established alternative treatment options using traditional surgical approaches, several considerations are important for institutions and operators planning to implement these new technologies.

Defining operator and institutional requirements for these novel therapies is an important first step in ensuring their optimal implementation.

Establishing a structural heart disease intervention therapy program requires several key components (Tables 1 and 2). The defining principle is that this effort is a joint, institutionally-based activity for cardiologists and cardiac surgeons (1,4). Thus, the specialty that provides some of these components will vary from program to program. A transcatheter aortic valve replacement (TAVR) program that uses only one specialty is fundamentally deficient, and valve therapy programs should not be established without this multidisciplinary partnership. Comprehensive multidisciplinary teams (MDTs) are, therefore, required for transcatheter valve therapies.

Knowledge Base and Skills

The critical cornerstone for establishing a transcatheter valve program is the formal collaborative effort between interventional cardiologists and cardiac surgeons. This element is essential for establishing a transcatheter valve program. No one individual, group, or specialty possesses all the necessary skills for best patient outcomes (1,5). The over-arching goal of these programs must be to provide the best possible patient-centered care (1,6).

As these are new techniques, the correlation between operator experience and performance metrics for these procedures has yet to be established. The current pool of trained individuals is comprised predominantly of those who have participated in industry-sponsored trials aimed at device approval. Therefore, the translation of currently available experiences with transcatheter valve therapies to the “real world” has yet to be evaluated in the United States.

Several core concepts should be implemented for all physicians performing these procedures, irrespective of their spe-
Major vascular complication 30 day all-cause neurologic events including transient ischemic attack

aAccording to VARC-2 (Valve Academic Research Consortium) (9a) definitions.

All cases must be submitted to a single national database

Ongoing continuing medical education (CME) (or nursing/technologist

60% 1-year survival rate for nonoperable patients (cohort b)—after the

90% Institutional follow-up

30 day all-cause mortality "Inoperable" (PARTNER Cohort B) TAVR Patients

Table 2. Volume and Outcomes for Continued Certification for Both New and Existing TAVR Programs Applies to “Inoperable” (PARTNER Cohort B) TAVR Patients

<table>
<thead>
<tr>
<th>Program volume of 20 TAVR per year or 40 per 2 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 day all-cause mortality &lt;1.5%</td>
</tr>
<tr>
<td>30 day all-cause neurologic events including transient ischemic attack (TIAs) &lt;1.5%</td>
</tr>
<tr>
<td>Major vascular complication &lt;1.5%*</td>
</tr>
<tr>
<td>&lt;90% Institutional follow-up</td>
</tr>
<tr>
<td>60% 1-year survival rate for nonoperative patients (cohort b)—after the program has been running for 2 years (2-year average)</td>
</tr>
<tr>
<td>Ongoing continuing medical education (CME) (or nursing/technologist equivalent) of 10 hr per year of relevant material</td>
</tr>
<tr>
<td>All cases must be submitted to a single national database</td>
</tr>
</tbody>
</table>

*According to VARC-2 (Valve Academic Research Consortium) (9a) definitions.

Table 1. Transcatheter Aortic Valve Replacement: Criteria for New and Existing Programs

<table>
<thead>
<tr>
<th>New Programs</th>
<th>Institutional Interventional Program</th>
<th>TAVR Interventionalist</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,000 cath/400 PCI per year*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 Structural procedures lifetime or 30 left sided structural per year of which 60% should be balloon aortic valvuloplasty (Left sided procedures include EVAR, TEVAR, BALLOON AORTIC VALVE (BAV), aortic valve (AV) and mitral valve (MV) prosthetic leak closures and ventricular septal defect [VSD] closures), (atrial septal defect/patent foramen oval (ASD/PFO) closure are not considered left sided procedures)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suitable training on devices to be used</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Institutional Surgical Program</th>
<th>TAVR Surgeon</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 Total AVR per year of which at least 10 aortic valve replacement (AVR) should be high-risk (STS score ≥6)</td>
<td></td>
</tr>
<tr>
<td>Minimum of 2 institutionally-based cardiac surgeons in program (more than 50% time at hospital with surgical program)</td>
<td></td>
</tr>
<tr>
<td>100 AVR career, at least 10 of which are “high-risk” (STS score ≥6) or 25 AVR per year or 50 AVR in 2 years and at least 20 AVR in last year prior to TAVR initiation</td>
<td></td>
</tr>
<tr>
<td>Experience with, and management of, peripherally inserted cardiopulmonary bypass</td>
<td></td>
</tr>
<tr>
<td>Experience with open retroperitoneal exposure of, and surgical intervention on, the iliac arteries</td>
<td></td>
</tr>
<tr>
<td>Suitable training on devices to be used</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Training</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiologists must be board certified/eligible in interventional cardiology</td>
</tr>
<tr>
<td>Surgeons must be board certified/eligible in thoracic surgery</td>
</tr>
<tr>
<td>Additional operators who are trained or experienced in structural heart disease, and have unrestricted hospital privileges in structural procedures, may also be part of the interventional operating team with the interventional cardiologist and cardiovascular surgeon</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Existing Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs in existence &gt;18 months: 30 TAVR (total experience)</td>
</tr>
<tr>
<td>Programs in existence &lt;18 months: 2 per month</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Training</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiologists must be board certified/eligible in interventional cardiology</td>
</tr>
<tr>
<td>Surgeons must be board certified/eligible in thoracic surgery</td>
</tr>
<tr>
<td>Additional operators who are trained or experienced in structural heart disease, and have unrestricted hospital privileges in structural procedures, may also be part of the interventional operating team with the interventional cardiologist and cardiovascular surgeon</td>
</tr>
</tbody>
</table>

With acceptable outcomes for conventional procedures compared to NCDR benchmarks.

The ability to interpret echocardiographic and other radiographic images (obtained at baseline, during the procedure, and follow-up) is critically important. MDTs and procedural teams need to possess echocardiographic interpretation skills for transthoracic and transesophageal studies. The use of three-dimensional (3D) and four-dimensional echoes may evolve to become essential diagnostic tools. Expertise in the interpretation of computed tomography (CT) scans of the iliofemoral vessels, cardiac anatomy, as well as aortic valvular anatomy, is critical for determining patient eligibility and the approach for procedures (8,10).

As noted, there is as yet no demonstrated direct correlation between operator experience with specific procedures and the skills necessary to perform transcatheter valve procedures, although there are some procedures that require similar prerequisite skills such as balloon aortic valvuloplasty (BAV) for TAVR. There are, however, some core concepts that professional societies have accepted as important for both facilities and operators (1,11,12). Minimum training for specific procedures and devices will, for the immediate future, be primarily dictated by FDA approval requirements. Simulation is likely to play a significant role in technical training and proficiency maintenance for these evolving procedures (13–17). As these procedures become integrated into mainstream care delivery, the strategy for training will likely need to be revised.

Minimum requirements for transcatheter valve therapies include an understanding of basic radiation safety necessary for optimal imaging, operator and patient exposure protection, and knowledge of the use of X-ray contrast agents, which may not be standard in cardiac surgery training and experience.

Training in the use of closed systems for hemodynamic monitoring and contrast injections will result in optimal integration into catheterization laboratories and hybrid environments. Catheter and wire skills, including knowl-
edge of the use of various techniques and the equipment available to access complex anatomy and negotiating necessary vascular and anatomic structures are required. Understanding of the interplay of wires, catheters, and anatomy is required for completion of these procedures. These skills can be acquired in a variety of ways. Prior experience with a variety of interventional techniques is important. These include but are not limited to:

- Coronary diagnostic procedures
- Coronary interventions
- Peripheral vascular diagnostic procedures
- Peripheral vascular interventions
- Balloon aortic, mitral, and pulmonic valve dilatation
- Stent implantation in right ventricle outflow tract and pulmonary arteries
- Intra-aortic balloon pump (IABP), other cardiac support device placement, including initiation of percutaneous cardiopulmonary bypass
- Percutaneous ventricular assist device placement
- Endovascular aneurysm repair (EVAR) or thoracic endovascular aortic repair (TEVAR) procedures
- Transseptal techniques
- Coronary sinus access
- Large vessel access and closure

Operators should also have experience with specific catheter-based techniques required for valve interventions. Similarly, surgeons should have experience with transapical approaches for left ventricular assist device placement and care of similar high-risk patients to perform transapical TAVR (11,12,18). The experience of an interventionalist or surgeon should be relevant to the transcatheter valve procedure undertaken. In this document, attention will focus on cardiac surgery and interventional cardiology experience relevant to aortic valve intervention.

The concept of sterile technique must be completely understood and stringently applied to the delivery of transcatheter valve therapies. Interventionalists must understand and be able to function in an environment that has more stringent sterile technique requirements than are common in catheterization laboratories. As one of the leaders of the team performing these procedures, the interventionalist must be able to enforce compliance with these standards. These procedures may involve open or partially open surgical components. Also, large devices that possess the same risk of infection as conventional valve prostheses will be implanted, especially for valve replacement procedures. Operating theater standards for sterile technique are, therefore, mandatory to ensure best patient outcomes.

**Facilities**

The institution should have an active valvular heart disease surgical program with at least two institutionally-based cardiac surgeons experienced in valvular surgery, and should contain a full range of diagnostic imaging and therapeutic facilities including:

1. Cardiac catheterization laboratory or hybrid operating room (OR)/cath lab equipped with a fixed radiographic imaging system with flat-panel fluoroscopy, offering catheterization laboratory quality imaging. A biplane unit may be advantageous, particularly for congenital heart disease.
2. Noninvasive imaging
   b. Vascular laboratory (noninvasive) with vascular specialists capable of performing and interpreting vascular studies.
   c. CT laboratory with CT technologists and specialists who can acquire and interpret cardiac CT studies.
3. Physical space—The implantation suite must have a sterile environment that meets OR standards. Furthermore, it must have sufficient space to accommodate the necessary equipment for uncomplicated implantations as well as any additional equipment that may be necessary in the event of complications. This includes space for anesthesiology, echocardiography, and cardiopulmonary bypass equipment and personnel. A specifically designed hybrid OR interventional suite is ideal; however, in the absence of such a facility, the interventional cardiac suite should have:
   a. Circulating heating, ventilation, and air conditioning laminar flow diffusers (providing smooth, undisturbed air flow and usually placed directly over the procedure table) to meet air requirements for surgery rooms.
   b. Asymmetrical/symmetrical six-lamp 2 × 4 troffers (the inverted, usually metal trough suspended from the ceiling as a fixture for fluorescent lighting) to provide adequate high-output lighting for surgical intervention.
   c. Adequate number of power receptacles that meet surgical equipment requirements.
   d. Capability of running cardiopulmonary bypass apparatus in the interventional suite.
   e. Gas outlets for the anesthesia machine.
   f. Adequate room size to accommodate the standard equipment required in a cardiac catheterization laboratory (e.g., high-definition displays and monitors, O₂ analyzer, defibrillator/resuscitation cart, O₂ supply, suction, compressed air, CO-oximeter, activated clotting time analyzer).
   g. Minimum room size of 800 square feet (74.3 m²) to accommodate echocardiographic equipment, sonographers, anesthesia equipment, emergency CT surgi-
cal team and cardiopulmonary bypass equipment (e.g., surgeon, assistant, scrub tech, pump techs), if needed.

4. Fungible equipment—The interventional suite should stock a large variety of fungible equipment, including various access kits, endovascular sheath and introducers ranging from 4 to 26 F in various lengths, a wide range of guide wires for various purposes, cardiac diagnostic and interventional catheters, vascular closure devices, balloon dilatation catheters ranging from 2 to 30 mm in diameter and of various lengths and profiles, bare metal and covered stents (e.g., coronary and peripheral), occlusive vascular devices, snares and other retrieval devices, drainage catheters, and various implantable device sizes with their delivery systems.

5. Postprocedure intensive care facility with personnel experienced in managing patients who have undergone conventional open heart valve procedures.

6. Use of mobile C-arm imaging system in an OR is not adequate.

7. HYBRID OR—The “2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update” will outline the specifications for a hybrid Cath Lab/OR (18a). Though this is preferable, it is not a prerequisite since it is not available at many institutions.

Most importantly, there must be dedication on the part of the hospital to provide these services and support, both financially and with no time constraints on the personnel involved. A dedicated administrator as a member of the team is necessary.

Other Institutional Resources

For preprocedure and postprocedure care and joint formal multidisciplinary patient consultation, adequate outpatient clinical care facilities are necessary. Appropriate office space for the medical, nursing, and technical personnel involved is also required, preferably in a central setting. Ancillary testing facilities (i.e., pulmonary function, echocardiography, vascular Duplex scanning, clinical laboratory, multislice CT) should be of high quality and able to accommodate the patient load on a timely basis.

By their very nature, these complex procedures should only be performed in institutions that currently and routinely perform large volumes of surgical aortic valve operations with outcomes that equal or exceed those established nationally for similar procedures. Similarly, only institutions with interventional cardiology programs that have established and successful programs with BAV, catheter closure of periprosthetic valvular leaks, insertion of ventricular septal closure devices with outcomes that equal or exceed those established nationally for similar procedures should develop an integrated structural heart MDT.

The institutional commitment required for a successful program goes beyond the necessary space, personnel, and specialized facilities set forth above. The complex and time consuming preprocedure patient triage process and the amount and intensity of postprocedure patient care after discharge are very labor intensive for the physician and nursing staff, as are the informed consents and communications with patients, families, and referring providers. In addition to supporting the core nursing and technical support staff, arrangements between the institution and the physicians need to be structured to reimburse physician efforts dedicated to nonreimbursable hours of clinical care and medical management of the program.

The complexity of transcatheter valve procedures and the magnitude of institutional resources required are similar to established heart transplant and cardiac assist device programs, where dedicated professionals, a minimum of infrastructure, MDT, registered nurse/nurse practitioner (NP), providers, coordinators, databases, and quality reporting are essential for optimal patient outcomes (1). This concept was endorsed by the Centers for Medicare and Medicaid Services (CMS) through the establishment of certification criteria for the use of heart transplantation and cardiac assist devices in centers and, moreover, for eligibility for reimbursement of services provided. The same regulatory system was applied to professionals providing these services. Transcatheter valve treatment programs should undergo a similar regulatory process with CMS endorsement. Centers should be approved for transcatheter aortic valve programs based on a minimum number of cases per year, and perioperative and 1-year outcomes above a minimum threshold.

Long-term outcome reporting is obligatory, to track not only survival, but also other parameters including periprocedural complications (CVA, vascular, renal, infectious, etc.), aortic regurgitation, the need for reintervention, subsequent surgery, and quality of life. This type of reporting is essential, since long-term outcome goals for these new procedures have not been established at this early stage. Participation in a national data registry (e.g., STS/ACC TVT Registry) is mandatory (1).

Multi-Disciplinary Team

The use of a team approach has been shown to improve outcomes in these types of complex procedures (19). The MDT necessary for a TAVR program is highlighted by the collaboration between the interventional cardiologist and cardiac surgeon (1). The MDT, however, goes well beyond this collaboration, and must include key providers from other physician groups (e.g., anesthesiology, radiology, noninvasive cardiology, intensive care). In addition to the individual physicians, other components that extend to various departments are necessary. The idea that the MDT is comprised of individual physicians working in a room performing the procedures is a superficial view that does not
take into account the level of resources necessary for a
successful valve therapy program. The interaction among
specialists in the MDT is fundamental, particularly for
preprocedure patient evaluation and selection. It is equally
fundamental that the patient be at the very center of all
discussions and decision-making regarding the best ther-
apy in her/his particular circumstance. While there is
great excitement about the application of transcatheter
valve therapies, most of these therapies will only be
indicated for a small portion of the population for the
immediate future. Proper decision-making and determi-
nation of best options for any given patient require an
evaluation by the MDT (20).

On-site valve surgery is an essential component of any
valve therapy program. The requirement for on-site valve
surgery is based not only on the potential need for emer-
gency or “back-up” surgery for percutaneous patients but
more importantly on the quality of patient evaluation and
selection, decision-making, intraprocedure management,
and postprocedure care and outcomes.

A cardiac surgeon and an interventional cardiologist must
evaluate every case. Interplay between interventional cardi-
ologists and cardiac surgeons represent only part of the
benefit of the MDT (1). As noted above, additional critical
contributions are provided by cardiac anesthesiologists, by
imaging specialists in both cardiology and radiology, and by
the many people who extend beyond the physician members
of the team. The MDT is led by a core of physicians from
interventional cardiology, cardiac surgery, cardiac anesthe-
siologist, and intensive care and cardiac imaging depart-
ments, along with congenital heart disease specialists and
surgeons, in some instances. Depending on the institutional
organization and the needs of the patient, vascular surgery
and interventional radiology departments may also partici-
pate in the MDT. Additional team members include NPs
from all of these fields, research coordinators, and a dedi-
cated administrator.

The function of the MDT is essential in preprocedure
patient selection, intraprocedure management and problem
solving, postprocedure management, postdischarge follow-
up, and outcome studies. During procedures, emergencies
or unanticipated needs may arise as a matter of course even
in the most straightforward situation. The immediate avail-
ability of MDT support to help with decision-making or
with therapy is essential. A clear definition of roles for
different specialties as well as effective communication,
which may be different from that of conventional proce-
dures, is critical for successful outcomes. Difficult postpro-
cedure courses are common in the high-risk patients who
comprise a large part of the target population for both
transcatheter and operative valve therapies. A team ap-
proach to problem solving in this setting is critical. Another
important part of patient management is the familiarity that
the intensive care unit and the monitored step-down floor
staff have with the specific details of each form of valve
therapy. After the postprocedure management phase, long-
term, posthospital follow-up for this select group of patients
is also part of the MDT’s responsibility. Planning for and
resourcing this important phase of care is incumbent on the
MDT. Post approval registries (e.g., STS/ACC TVT Reg-
istry) (1) will be required for many of the new transcatheter
valve therapies, and, therefore, a data collection/research
unit within the MDT is another required component.

For sites with no prior trial experience in aortic trans-
catheter therapies, background experience from related pro-
cedures is important. The surgical use of ventricular assist
device support or apical conduit therapy for aortic stenosis
or left ventricular apical venting during aortic aneurysm
procedures provides excellent experience for management of
apical access for TAVR. For transcatheter procedures that
do not directly involve the surgeon as a procedure operator,
the role of the cardiac surgeon remains critically important.
The surgeon has many roles and is often a patient advocate
and/or referring physician, and is a necessary scientific study
participant in all of these device applications. The surgeon is
familiar with established standards of surgical care for
application in transcatheter therapies and is frequently in
charge of assessing high-risk patients for catheter-based
therapy as an alternative to surgery. In a valve therapy
program, neither the surgeon nor the cardiologist should be
in charge of the assessment, but rather the MDT. In all
transcatheter aortic procedures, the interventionalist and the
surgeon should be present for the critical portions of the
procedure.

Another mechanism for promoting a team approach that
involves both surgeons and cardiologists is split or shared
physician reimbursement for these procedures, which this
writing group strongly endorses. This important principle
will ensure that surgeons and cardiologists participate jointly
in performing procedures, and that each patient receives the
best and most patient-centered treatment.

The MDT should meet formally as a group on a regular
basis (aside from the usual “cath conference”) to review all
patients referred for procedures, performance of recent
procedures (to discuss both favorable and unfavorable out-
comes), and follow-up of prior procedures.

Function of the MDT

Programmatic success depends on the ability of the MDT
to function effectively in the best interest of a given patient.
To do so, the MDT must work cohesively through the
processes of patient selection, procedural planning, proce-
dural conduct, periprocedural care, and longitudinal
follow-up (1). Through each phase of this continuum, the
individual skills of the MDT members should be brought to
bear on the process.

The procedural success of transcatheter valve therapies
begins with patient selection. Given the complexity of the
decision-making process surrounding these procedures, it is
necessary that all MDT members provide objective input
and judgments from the outset of a patient evaluation (1). In order that true informed consent be obtained, the patient must remain at the center of the deliberations of the MDT at all times, and must be involved in the discussions regarding her/his therapeutic approach and goals. The patient selection process may be initiated by use of regularly scheduled patient selection conferences attended by all MDT members. Such conferences are analogous to transplant patient selection committee meetings, and provide a venue in which patient-specific data and imaging are formally presented and discussed by the MDT. The respective expertise of each discipline represented among MDT members may then be synthesized into a patient-specific recommendation.

Direct patient evaluation by cardiologists and cardiac surgeons may be accomplished jointly and, if possible, simultaneously in a venue such as a multidisciplinary valve program clinic. Not only does such a clinic provide convenience for the many patients who are elderly and fragile, but it also provides an opportunity for cardiac surgeons and cardiologists to jointly examine and evaluate complex patients.

In so doing, the expertise and judgment of both disciplines may be woven into a patient-specific decision. The participation of anesthesiologists in these clinics may also be useful.

Following the decision that a given patient is an appropriate candidate for TAVR, the procedure must then be carefully planned. Cardiac surgical teams are familiar with, and routinely use the concept of, “preprocedure briefings” before complex cardiac surgical operations. In such briefings, all team members (i.e., surgeons, anesthesiologists, perfusionists, nurses, and technicians) discuss the intended procedure, including the steps of the planned procedure, the specific tools and equipment needed (beyond those typically used), the possible complications that may arise during the course of the procedure, and the contingency plans that will be implemented should the unexpected occur (1). All members of the team may then initiate the planned procedure with a common understanding of its conduct and what will happen if the plan needs to change.

As integral members of the MDT, the cardiologist, cardiovascular surgeon, and the catheterization team will participate actively in this preprocedure planning and MDT briefing, which is so important for the procedural success of transcatheter valve therapies. During the procedure, emergency situations and unexpected needs may arise. The immediate availability of MDT physician support in emergency decision-making and therapy is essential. It is, therefore, important that the roles of the various specialties be clearly delineated during preprocedure planning.

Patients who undergo transcatheter valve therapies are often elderly and frail with multiple comorbidities. Postprocedure care of such patients may be difficult and entail the management of multiple organ system dysfunctions. In many cases, the initial postprocedure care should be provided in an intensive care setting. A team approach to the care of these patients and to problem solving is important and should include physicians skilled in critical care medicine. Once in-patients are able to leave the intensive care environment, they should be attended by a unit specializing in the care of patients with cardiac diseases, and this unit should be equipped with telemetry-monitored beds. Again, a team approach is important for success. The team of physicians, nurses, occupational and physical therapists, and other members must have an understanding of the pathophysiology of the particular valve condition, as well as the nuances of care for patients who have undergone cardiac surgery and interventional cardiology procedures.

Procedural success of transcatheter valve therapies must be determined via longitudinal outcomes. Long-term follow-up of these patients is an important element of the MDT approach. Post-FDA approval registries (e.g., STS/ACC TVT Registry) will be required for most transcatheter valve therapies (1). Therefore, a long-term relationship between the patient and the MDT must be established to undertake the needed alterations in medical therapy, serial echocardiographic imaging, and monitoring of devices. Likewise, changes in patient functional status, heart failure class, potential device-related complications, and other such conditions must be carefully tracked. A valve program clinic can provide a venue for this type of long-term follow-up.

The postmarket surveillance of transcatheter valve devices will be an extremely important function of the MDT. Participation in device-specific registries (e.g., STS/ACC TVT Registry) can be challenging and requires an institutional infrastructure and commitment that includes experienced data managers with a background in cardiac disease, funding, office space, and computer resources. It requires a clinical research unit with rigorous attention to detail, and the collection of accurate data as an integral part of the function of the MDT.

Criteria for Establishing a Transcatheter Valve Program and Maintenance of Competence

An important issue in the establishment of a transcatheter valve program is the clinical or referral base for ensuring an adequate number of patients to provide for the viability of a program. The requirements for the establishment of a successful transcatheter valve program are described in Table 1.

Once chosen for participation as TAVR programs, either as existing programs, or as new programs, to maintain ongoing approval for participation, sites will be monitored to ensure that they continue to satisfy both the volume and outcomes criteria as described in Table 2.

Unlike the experience with PCI, where data attest to the relationship between the volume of procedures and outcomes, there are little or no data on which to draw conclusions as to the volume–outcome relationship for TAVR. Therefore, these recommendations are constructed...
to: 1) ensure patient safety, 2) demonstrate that there is a commitment on the part of the institution to the structural heart disease program, and 3) use existing volume as a surrogate for an established valve program to ensure adequate patient volumes for the establishment of a sustainable and high-quality transcatheter valve program. As experience grows and more data become available, these recommendations will undoubtedly be refined.

**Aortic Valve Replacement**

Surgical aortic valve replacement is the treatment of choice for patients with severe aortic valve disease (1). However, a significant percentage of those patients are not offered the procedure or simply refuse to undergo it on the basis of excessive risks, both real and perceived (21). It is in this context that the possibility of transcatheter aortic valve implantation has become a reality for patients outside of the United States. Furthermore, the cohort B results of the PARTNER (Placement of Aortic Transcatheter) trial (nonoperable patients) would indicate that medical therapy, including BAV, should be reserved only for patients who do not qualify for the procedure on the basis of their anatomy or clinical characteristics (22). Considering the reports of successful transcatheter treatment of aortic valve stenosis using balloons (23) and subsequent reports of poor long-term outcomes due to early restenosis (24), the idea of developing a transcatheter aortic valve was a logical progression. Initial animal studies (25) and subsequent human implantations have led to the progressive development of this technology.

Results from the PARTNER trial using the Edwards Sapien Valve (Edwards Lifesciences, Irvine, CA), the first randomized trial of this technology, have established its safety, and high-quality transcatheter valve program. As experience grows and more data become available, these recommendations will undoubtedly be refined.

**Aortic Valve Replacement**

Surgical aortic valve replacement is the treatment of choice for patients with severe aortic valve disease (1). However, a significant percentage of those patients are not offered the procedure or simply refuse to undergo it on the basis of excessive risks, both real and perceived (21). It is in this context that the possibility of transcatheter aortic valve implantation has become a reality for patients outside of the United States. Furthermore, the cohort B results of the PARTNER (Placement of Aortic Transcatheter) trial (nonoperable patients) would indicate that medical therapy, including BAV, should be reserved only for patients who do not qualify for the procedure on the basis of their anatomy or clinical characteristics (22). Considering the reports of successful transcatheter treatment of aortic valve stenosis using balloons (23) and subsequent reports of poor long-term outcomes due to early restenosis (24), the idea of developing a transcatheter aortic valve was a logical progression. Initial animal studies (25) and subsequent human implantations have led to the progressive development of this technology.

Results from the PARTNER trial using the Edwards Sapien Valve (Edwards Lifesciences, Irvine, CA), the first randomized trial of this technology, have established its safety, and high-quality transcatheter valve program. As experience grows and more data become available, these recommendations will undoubtedly be refined.

**Aortic Valve Replacement**

Surgical aortic valve replacement is the treatment of choice for patients with severe aortic valve disease (1). However, a significant percentage of those patients are not offered the procedure or simply refuse to undergo it on the basis of excessive risks, both real and perceived (21). It is in this context that the possibility of transcatheter aortic valve implantation has become a reality for patients outside of the United States. Furthermore, the cohort B results of the PARTNER (Placement of Aortic Transcatheter) trial (nonoperable patients) would indicate that medical therapy, including BAV, should be reserved only for patients who do not qualify for the procedure on the basis of their anatomy or clinical characteristics (22). Considering the reports of successful transcatheter treatment of aortic valve stenosis using balloons (23) and subsequent reports of poor long-term outcomes due to early restenosis (24), the idea of developing a transcatheter aortic valve was a logical progression. Initial animal studies (25) and subsequent human implantations have led to the progressive development of this technology.

Results from the PARTNER trial using the Edwards Sapien Valve (Edwards Lifesciences, Irvine, CA), the first randomized trial of this technology, have established its safety, and high-quality transcatheter valve program. As experience grows and more data become available, these recommendations will undoubtedly be refined.

**Aortic Valve Replacement**

Surgical aortic valve replacement is the treatment of choice for patients with severe aortic valve disease (1). However, a significant percentage of those patients are not offered the procedure or simply refuse to undergo it on the basis of excessive risks, both real and perceived (21). It is in this context that the possibility of transcatheter aortic valve implantation has become a reality for patients outside of the United States. Furthermore, the cohort B results of the PARTNER (Placement of Aortic Transcatheter) trial (nonoperable patients) would indicate that medical therapy, including BAV, should be reserved only for patients who do not qualify for the procedure on the basis of their anatomy or clinical characteristics (22). Considering the reports of successful transcatheter treatment of aortic valve stenosis using balloons (23) and subsequent reports of poor long-term outcomes due to early restenosis (24), the idea of developing a transcatheter aortic valve was a logical progression. Initial animal studies (25) and subsequent human implantations have led to the progressive development of this technology.

Results from the PARTNER trial using the Edwards Sapien Valve (Edwards Lifesciences, Irvine, CA), the first randomized trial of this technology, have established its safety, and high-quality transcatheter valve program. As experience grows and more data become available, these recommendations will undoubtedly be refined.
follow-up for survival and valve-related complications and reinterventions. These valve repair and replacement procedures should be registered in databases capable of providing both acute outcome and long-term follow-up data.

Early postprocedure morbidity and mortality analyses, while important for initial and continued implant safety assessment, are not sufficient to evaluate the efficacy of valve repair or replacement prostheses. Studies on long-term follow-up survival and, more importantly, structural valve degeneration, and the need for reintervention, are essential. Recent attempts to link the STS National Database to an administrative survival database (Social Security Death Master File) or to CMS Medicare data have been promising; however, survival data alone will not be sufficient for transcatheter valve registries (e.g., STS/ACC TVT Registry [33]). Risk adjustment using only administrative data is challenging and may be more important in this highly complex patient population. Transcatheter valve registries must incorporate late assessment of structural valve degeneration and the need for late reoperation or reintervention.

Long-term function data is also essential before application of new valve repair or replacement technology can be considered for lower risk and younger patients. Clinicians must be careful not to extrapolate outcomes generated during FDA trials to patients that do not reasonably approximate the trial study populations. At present, it is not acceptable for clinicians to apply “off label” transcatheter techniques to patients who are otherwise excellent candidates for conventional valve repair or replacement outside the confines of a randomized, controlled trial or, at a minimum, multicenter, national, prospective studies.

The potential negative impact of a valve prosthesis recall, in regards to the increased risk associated with reoperative surgery for a permanent implant, far outweighs that associated with the removal of a pharmacologic agent from the market (34). Thus, the allocation of adequate funding to allow complete follow-up studies is essential, including financial support from industry, the FDA, National Institutes of Health, CMS, and professional societies, with scientific oversight distanced from industry and potential conflicts of interest. Postmarket surveillance governed solely by industry self-regulation can be of dubious value. In a 2005 editorial, Eugene Blackstone cautioned, “Industry has not developed a viable mechanism for dealing with ‘bad news,’ the disclosure of which often leads to the demise of the company” (35). The Interagency Registry for Mechanically Assisted Circulatory Support exemplifies a potentially efficient model that could be emulated by professional societies for monitoring transcatheter inventions during the next decade, during which durability data will be generated (36).

Transcatheter valve repair or replacement devices are unique in that an understanding not only of early risk, but also of long-term durability, is essential for determining the appropriate patient subgroups for these therapies. In our opinion, it is the responsibility of professional societies to ensure adequate long-term data monitoring and provide oversight and guidance to industry on the expectations for continued monitoring beyond the FDA approval phase of device development and implementation. Individual centers are also responsible for critically evaluating their own experience, through local and regional quality improvement initiatives, and for participating in national databases and registries (e.g., STS/ACC TVT Registry) that facilitate continued safety and efficacy in the assessment of novel, and, as yet, unproven, therapeutic options. Components of a national/international registry should include preoperative risk factors and valve assessment, intraoperative details, early postoperative morbidity, and late follow-up including survival, need for reintervention, functional class, device-related complications and late assessment of valve performance. It is inappropriate to perform these novel and innovative procedures without the institutional infrastructure to ensure adequate early data collection and later follow-up.

REFERENCES


<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Bavariaa</td>
<td>Hospital of the University of Pennsylvania Health System Cardiopulmonary Surgery—Vice-Chief, Division of Cardiology; Brooke Roberts-William M. Measey Professor of Surgery; Director, Thoracic Aortic Surgery Program</td>
<td>St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>Medtronic Vascular</td>
<td>Edwards Lifesciencesb</td>
<td>None</td>
</tr>
<tr>
<td>R. Morton (Chip) Bolman</td>
<td>Harvard Medical School—Chief, Division of Cardiac Surgery; Professor of Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Duke Cameron</td>
<td>The Johns Hopkins Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Larry Deana</td>
<td>University of Washington School of Medicine—Professor of Medicine and Surgery</td>
<td>Emageon Phillips Medical</td>
<td>None</td>
<td>None</td>
<td>Edwards Lifesciencesb</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ted Feldmana</td>
<td>Evanston Northwestern Healthcare Cardiology Division—Director, Cardiac Catheterization Laboratory</td>
<td>Abbott Boston Scientific Lifesciences Edwards W.L. Gore</td>
<td>None</td>
<td>None</td>
<td>Abbott Boston Scientific Edwards Edwards Lifesciences W.L. Gore</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David Fullerton</td>
<td>University of Colorado School of Medicine—Chief, Cardiothoracic Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziyad M. Hijazi</td>
<td>Rush University Medical Center—Professor, Pediatrics and Internal Medicine; Director for the Center of Congenital and Structural Heart Disease</td>
<td>Edwards LifeSciences NuMEDc</td>
<td>None</td>
<td>None</td>
<td>Colibri Heart Valveb</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric Horlicka</td>
<td>Toronto General Hospital—Asst. Professor of Medicine, University Health Network</td>
<td>Abbott Vascular AGA Cordis Edwards Lifesciences Medtronic W.L. Gore</td>
<td>Biosense Webster</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>D. Craig Millera</td>
<td>Stanford University Medical School Dept. Cardiopulmonary Surgery—Thelma and Henry Doelger Professor of Cardiovascular Surgery; Cardiovascular Surgical Physiology Research Laboratories—Director</td>
<td>Abbott Vascular MitraClip Medtronic Cardiovascular Division St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>Edwards Lifesciences (PARTNER Trial)b</td>
<td>Edwards Lifesciences (PARTNER Trial)b</td>
<td>None</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker’s Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Institutional, Organizational, or Other Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>------------------</td>
<td>------------</td>
<td>------------</td>
<td>------------------</td>
<td>---------------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Marc R. Moon</td>
<td>Barnes-Jewish Hospital—Joseph Bancroft Professor of Surgery, Division of Cardiothoracic Surgery; Program Director, Thoracic Surgery Residency Program</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Richard R. Ringel</td>
<td>Johns Hopkins School of Medicine—Associate Professor of Pediatrics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Carlos E. Ruiz</td>
<td>Lenox Hill Heart and Vascular Institute of New York—Professor and Chief, Division of Pediatric Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Carl Tommaso</td>
<td>North Shore University HealthSystem—Medical Director of Cardiac Cath Lab</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alfred Trento</td>
<td>Cedar Sinai Medical Center—Director of Division of Cardiothoracic Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bonnie Weiner*</td>
<td>Saint Vincent Hospital at Worcester Medical Center/Fallon Clinic—Director of Interventional Cardiology Research; Imaging Core Lab Services—President; Boston Biomedical Associates—Medical Director</td>
<td>LabCoat/Boston Scientific(^c)</td>
<td>Medtronic</td>
<td>None</td>
<td>None</td>
<td>Accreditation for Cardiovascular Excellence(^c) Imaging Core Lab Services(^b)</td>
<td>None</td>
</tr>
<tr>
<td>Evan M. Zahn</td>
<td>Miami Children’s Hospital—Director of Cardiology</td>
<td>Medtronic(^c) Edwards Lifesciences(^b)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

According to the ACCF, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

*Recused from writing initial text and voting on document recommendations due to relevant relationships with industry to this document. \(^b\)No financial benefit. \(^c\)Significant relationship.
<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepak L. Bhatt</td>
<td>Official Reviewer—ACCF Task Force on Clinical Expert Consensus Documents</td>
<td>VA Boston Health Care System—Chief, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronicb</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ann Bolger</td>
<td>Content Reviewer—ACCF/AHA/ACP Task Force on Clinical Competence and Training</td>
<td>University of California, San Francisco—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Emmanouil Brilakis</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>UT Southwestern Medical School—Director, Cardiac Catheterization Laboratory, VA North Texas Healthcare System</td>
<td>St. Judeb</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>John H. Calhoon</td>
<td>Official Reviewer—STS</td>
<td>University of Texas Health Sciences Center—Professor and Chair, Department of Cardiothoracic Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>George Dangas</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>Mount Sinai Medical Center—Program Director, Interventional Cardiology</td>
<td>Abbott Boston Scientific Johnson &amp; Johnson Medtronic St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Abbott Vascularb</td>
<td>Plaintiff, Stroke, 2011</td>
</tr>
<tr>
<td>Fred H. Edwards</td>
<td>Official Reviewer—STS</td>
<td>Shands Jacksonville—University of Florida—Professor of Surgery; Chief, Cardiothoracic Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>James L. Fann</td>
<td>Official Reviewer—AATS</td>
<td>Stanford University School of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronicb</td>
<td>None</td>
</tr>
<tr>
<td>James Fasules</td>
<td>Senior Vice President, Advocacy</td>
<td>American College of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>T. Bruce Ferguson</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>East Carolina Heart Institute Brody School of Medicine at ECU—Professor of Surgery and Physiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Edwards Lifesciences</td>
<td>None</td>
</tr>
<tr>
<td>Mario J. Garcia</td>
<td>Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents</td>
<td>Montefiore Medical Center-Albert Einstein College of Medicine—Chief, Division of Cardiology</td>
<td>MD Imaging</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronicb</td>
<td>None</td>
</tr>
<tr>
<td>Federico Gentile</td>
<td>Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents</td>
<td>Centro Medico Diagnostico</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Leonard N. Girardi</td>
<td>Official Reviewer—AATS</td>
<td>New York-Presbyterian/Weill Cornell Medical College</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Steve Goldberg</td>
<td>Official Reviewer—SCAI</td>
<td>University of Washington Medical Center</td>
<td>AGA Medical</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Amplatzer Division of St. Jude Medical</td>
<td>Plaintiff, Patent Litigation, 2010</td>
</tr>
<tr>
<td>Frederick L. Grover</td>
<td>Content Reviewer—ACCF Surgeon Scientific Council</td>
<td>University of Colorado Department of Surgery—Professor and Chair</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peer Reviewer</td>
<td>Representation</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker’s Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>-------------------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Robert Guyton</td>
<td>Content Reviewer—ACC</td>
<td>Emory Clinic, Inc.—Professor and Chief, Division of Cardiopulmonary Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Defendant, Cardiac Surgery, 2011</td>
</tr>
<tr>
<td>Jonathan Halperin</td>
<td>Content Reviewer—ACCF/AHA/ACP Task Force on Clinical Competence and Training</td>
<td>Mount Sinai Medical Center—Professor of Medicine</td>
<td>Biotronix, Inc.</td>
<td>Edwards Lifesciences Johnson &amp; Johnson Ortho-McNeil/Janssen Pharmaceuticals</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Howard Herrmann</td>
<td>Official Reviewer—SCAI</td>
<td>University of Pennsylvania Medical Center</td>
<td>W.L. Gore</td>
<td>St. Jude Medical</td>
<td>None</td>
<td>Micro Interventional</td>
<td>Edward Lifesciences</td>
<td>None</td>
</tr>
<tr>
<td>Joerg Herrmann</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David R. Holmes, Jr.</td>
<td>ACFF/AATS/SCAI/STS TAVR Expert Consensus Document Writing Committee</td>
<td>Mayo Clinic—Consultant, CV Diseases</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sanjay Kaul</td>
<td>ACFF/AATS/SCAI/STS TAVR Expert Consensus Document Writing Committee</td>
<td>Cedars-Sinai Medical Center—Director, Cardiology Fellowship Training Program</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lloyd Klein</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>Rush-Presbyterian-St. Luke’s Medical Center—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joel S. Landzberg</td>
<td>Content Reviewer—ACCF Adult Congenital and Pediatric Cardiology Council</td>
<td>Westwood Cardiology Associates</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ehtisham Mahmud</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>University of California, San Diego—Professor of Medicine and Director,</td>
<td>Phillips Medical</td>
<td>Medtronic</td>
<td>None</td>
<td>None</td>
<td>Abbott Vascular, St. Jude Medical</td>
<td></td>
</tr>
<tr>
<td>James B. McClurken</td>
<td>Content Reviewer—ACCF Surgeon Scientific Council</td>
<td>Temple University Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Geno J. Merli</td>
<td>Content Reviewer—ACCF/AHA/ACP Task Force on Clinical Competence and Training</td>
<td>Jefferson Center for Vascular Disease—Director, Jefferson Medical College—Senior Vice President; Thomas Jefferson University Hospital—Chief Medical Officer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Issam Moussa</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>Mayo Clinic—Chair, Division of CV Diseases</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Brent J. Muhlestein</td>
<td>Content Reviewer—ACCF/AHA/ACP Task Force on Clinical Competence and Training</td>
<td>Intermountain Medical Center, Cardiology Department—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Defendant, Cardiac Catheterization, 2011</td>
</tr>
<tr>
<td>Srijith Naidu</td>
<td>Content Reviewer—ACCF Interventional Scientific Council</td>
<td>Winthrop University Hospital—Director, Cardiac Cath Lab</td>
<td>Abbott Vascular</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hani Najm</td>
<td>Content Reviewer—ACCF Surgeon Scientific Council</td>
<td>National Guard Health Affairs—President, Saudi Heart Association</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jennifer S. Nelson</td>
<td>Official Reviewer—STS</td>
<td>University of Michigan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peer Reviewer</td>
<td>Representation</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker's Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Institutional, Organizational, or other Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>------------</td>
<td>-----------------</td>
<td>-----------------------------</td>
<td>-----------------</td>
<td>----------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Ileana Piña</td>
<td>Content Reviewer—ACCF/AHA/ACP Task Force on Clinical Competence and Training</td>
<td>Montefiore Medical Center—Professor of Medicine and Epidemiology and Population Health</td>
<td>GE HealthCare</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Stephen Ramee</td>
<td>Official Reviewer—ACCF Board of Governors</td>
<td>Ochsner Clinic Foundation—Director, Cardiac Catheterization</td>
<td>None</td>
<td>None</td>
<td>Boston Scientific</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Richard Smalling</td>
<td>Content Reviewer—ACCF Surgeon Scientific Council</td>
<td>University of Texas Medical School—Jay Brent Sterling Professor of Cardiovascular Medicine</td>
<td>AGA Medical</td>
<td>None</td>
<td>None</td>
<td>AGA Medical Cordis</td>
<td>AGA Medical Cordis</td>
<td>None</td>
</tr>
<tr>
<td>Wilson Y. Szeto</td>
<td>Official Reviewer—STS</td>
<td>University of Pennsylvania</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vinod H. Thourani</td>
<td>Official Reviewer—STS</td>
<td>Emory University</td>
<td>Edwards Lifesciences Sorin Medical St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

According to the ACCF, a person has a relevant relationship if: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

AATS indicates American Association for Thoracic Surgery; ACCF, American College of Cardiology Foundation; SCAI, Society for Cardiovascular Angiography and Interventions; and STS, Society of Thoracic Surgeons.
Multisociety (AATS, ACCF, SCAI, and STS) Expert Consensus Statement: Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part 1: Transcatheter Aortic Valve Replacement


*J. Am. Coll. Cardiol.* 2012;59;2028-2042; originally published online Mar 1, 2012; doi:10.1016/j.jacc.2012.02.016

This information is current as of May 23, 2012